Sign Out
Non-Small Cell Lung Cancer (NSCLC): Pemetrexed in combination with cisplatin is indicated for the first-line therapy of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer.
Pemetrexed is indicated as a single-agent for the maintenance of patients with nonprogressive locally advanced or metastatic nonsquamous non-small cell lung cancer after 4 cycles first-line chemotherapy with platinum.
Pemetrexed is indicated as a single-agent for the treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer after prior chemotherapy.
Pemetrexed is not indicated for the treatment of patients with squamous cell non-small cell lung cancer.
Malignant Pleural Mesothelioma: Pemetrexed in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma who is not eligible for surgery.
Continue with Google